Who Is Not a Good Candidate for Ketamine Therapy? A Clinician's Guide

Who Is Not a Good Candidate for Ketamine Therapy?

Ketamine therapy eligibility is determined through an individualized clinical assessment rather than a universal checklist. Ketamine has been FDA-approved as an anesthetic since 1970 and has been on the World Health Organization's List of Essential Medicines since 1985.³

Off-label prescribing for mental health conditions is a well-established, legally accepted medical practice.⁴ However, certain medical and psychiatric conditions require careful screening to ensure patient safety.

Clinicians evaluate several major categories of medical and psychiatric conditions that generally make someone a poor candidate for this treatment.

• Active psychosis or schizophrenia: Ketamine's dissociative properties may exacerbate psychotic symptoms.⁵ Clinicians screen carefully for a personal or family history of psychotic disorders to prevent worsening these conditions.
• Uncontrolled hypertension or serious cardiovascular disease: Ketamine has sympathomimetic properties, meaning it temporarily stimulates the cardiovascular system. Individuals with uncontrolled high blood pressure, recent heart attacks, or unstable angina are typically excluded during cardiovascular screening.
• Active substance use disorder: Because ketamine is a Schedule III controlled substance, individuals with active, untreated substance use disorders may face elevated risks. Stable recovery with clinician oversight may be evaluated differently depending on the specific clinical context.
• Pregnancy or breastfeeding: Clinical trials ethically exclude pregnant women, resulting in limited safety data regarding fetal and neonatal exposure. Because of this unknown risk, pregnant or breastfeeding individuals are generally advised against starting ketamine therapy. For postpartum individuals who are not breastfeeding — which includes a significant portion of this population — this specific barrier does not apply, and eligibility is evaluated based on the standard screening criteria.
• Severe liver or kidney disease: The liver breaks down ketamine, and the kidneys filter it out of the body. Significant impairment in either organ system may cause the medication to build up unsafely, making these conditions a primary exclusion.
• Uncontrolled thyroid disease: Conditions such as hyperthyroidism already place excess stress on the cardiovascular system. Ketamine can compound this stress, making uncontrolled thyroid issues a significant medical risk.
• Elevated intracranial pressure or seizure history: Elevated intracranial pressure has historically been cited as a contraindication for ketamine; however, modern systematic reviews have challenged this view, with evidence suggesting ketamine does not increase intracranial pressure and may lower it in selected cases.⁶ Clinicians nonetheless screen for seizure history and neurological conditions as part of standard intake evaluation.

These conditions are not always binary disqualifiers — they are clinical considerations a licensed provider evaluates during your intake, individualizing the protocol to your specific health profile.

Does Ketamine Help Schizophrenia?

You may wonder whether ketamine has therapeutic applications for schizophrenia, or if people with this diagnosis can safely receive treatment for co-occurring conditions like depression. This is a common question as researchers continue to study how different medications affect the brain.

Ketamine's mechanism of action involves NMDA receptor modulation, and research into glutamatergic dysfunction in schizophrenia is an ongoing area of neuroscience. However, ketamine's dissociative effects can mimic or worsen positive psychotic symptoms, such as hallucinations, delusions, or disorganized thinking.

Current clinical consensus does not support ketamine as a treatment for schizophrenia. While researchers continue to study these neural pathways, most providers exclude individuals with active psychosis or a primary schizophrenia diagnosis from their treatment protocols.

In clinical practice today, a history of psychotic disorders remains one of the most consistently cited exclusion criteria.

Can You Take Ketamine on Antipsychotics or Benzodiazepines?

Antipsychotics and benzodiazepines are two of the most commonly asked-about medication classes regarding ketamine therapy eligibility. Understanding how these medications interact with ketamine is a critical part of the clinical screening process.

Neither medication class is an automatic disqualifier, but both require careful clinician evaluation.

• Antipsychotics: Some antipsychotic medications may blunt ketamine's therapeutic effects by antagonizing the same receptor pathways that ketamine modulates.⁷ Other antipsychotics may increase the risk of sedation during your session, requiring a clinician to review your specific dosage.
• Benzodiazepines: Benzodiazepines are central nervous system depressants that may reduce or alter ketamine's therapeutic window.⁸ Some clinical protocols require dose adjustments or temporary holds, while others evaluate the interaction on a case-by-case basis.

You should never abruptly discontinue benzodiazepines or adjust your medications without medical supervision, as this carries significant health risks. Always provide a complete medication list during your intake so your clinician can make safe, informed prescribing decisions.

What Makes Someone a Good Candidate for Ketamine Therapy?

Candidacy for ketamine therapy is not solely defined by what disqualifies you from treatment. Understanding who typically benefits from this medicine helps contextualize the clinical screening process.

A strong candidate for this treatment generally fits a specific clinical profile.

• Adults with depression, anxiety, or PTSD: Ketamine therapy has a well-established evidence base across these conditions, supported by decades of peer-reviewed research and clinical observation.⁹
• People seeking a different mechanism of action: Prior treatment failure is not a strict prerequisite for eligibility. However, individuals who have tried daily medications or talk therapy with limited improvement often find that ketamine offers a meaningfully different approach through enhanced neuroplasticity.
• People who are medically stable: Candidacy requires passing a comprehensive clinical evaluation. This assessment reviews your medical history, psychiatric background, current medications, and baseline vital signs.
• People willing to engage in a defined treatment framework: Ketamine therapy is most effective within a programmatic model that includes preparation, guided sessions, and integration. The treatment is designed to work within this supportive framework, which is where most people see the strongest results.
• People seeking an alternative to long-term daily medication: Some individuals are drawn to ketamine therapy specifically because it offers a time-limited, session-based treatment model rather than indefinite daily medication.

Eligibility is ultimately a clinical determination made by a licensed provider. The screening process exists to match the right people with the right treatment at the right time.

How Clinicians Evaluate Ketamine Therapy Eligibility

The clinical screening process involves a comprehensive evaluation that takes place between expressing interest and receiving your first session. This assessment ensures that the treatment aligns safely with your medical and psychological needs.

Clinicians walk through several specific evaluation components during your intake.

• Medical history review: Your provider will assess your cardiovascular health, liver and kidney function, thyroid status, and seizure history. They will also ask about any prior adverse reactions to anesthesia or ketamine.
• Psychiatric history assessment: This includes reviewing your current diagnoses, symptom severity, and any history of psychosis or mania. Your clinician will also discuss your trauma history and what previous treatments have or have not helped.
• Medication reconciliation: You will undergo a full review of your current prescriptions, over-the-counter supplements, and substance use. This helps identify potential interactions with medications like antipsychotics, benzodiazepines, MAOIs, and lithium.
• Psychosocial readiness: Your clinician will verify whether you have a safe home environment for treatment and access to a peer treatment monitor, which is required during sessions. They will also gauge your willingness to engage in integration practices.

This process is not a mere formality, but rather the mechanism through which safety is individualized to your unique health profile. A condition that excludes one person may be manageable for another depending on severity, stability, and the specific clinical context.

Is Ketamine Therapy Safe?

Ketamine's safety profile is one of the most extensively documented of any medicine used in psychiatric contexts. It has decades of clinical use data across anesthesia, emergency medicine, and mental health applications.

Understanding the safety of this treatment requires looking at several key dimensions.

• Common side effects: Some people experience temporary nausea, dizziness, or elevated blood pressure during or shortly after a session. In a peer-reviewed study of 11,441 Mindbloom patients receiving at-home ketamine therapy, side effects were reported in approximately 4–5% of participants.¹ These effects generally occur during the acute dosing window and are monitored during the session; when they occur, they typically lessen as ketamine's short-acting pharmacologic effects wear off during the post-session period.
• Dissociation: Dissociation is a known, often therapeutically meaningful aspect of ketamine treatment — not a side effect. Within a clinician-supervised setting with preparation materials and a peer treatment monitor present, most people find the experience manageable, and many describe it as the most valuable part of the session.
• Dependence potential: Dependence on ketamine refers to the development of tolerance and compulsive use patterns. This is primarily documented in chronic, unsupervised recreational use at frequencies and doses far exceeding therapeutic protocols.¹⁰ Within clinical programs using sub-anesthetic, clinician-determined dosing, dependence risk is mitigated through screening, defined session counts, and ongoing monitoring.
• Serious adverse events: In large-scale real-world data, serious adverse events during supervised ketamine therapy sessions occur at very low rates. In Mindbloom's peer-reviewed real-world outcomes study, these events occurred in fewer than 0.1% of sessions, with a discontinuation rate due to adverse events of 0.4%. Across more than 700,000 supervised sessions to date, this safety profile has remained consistent.¹

Safety is not an inherent property of any medicine, but rather a function of screening, clinical oversight, dosing protocols, and support. The question is not whether ketamine is safe in the abstract, but whether it is safe for a specific individual within a specific clinical framework.

How Clinician-Supervised Protocols Reduce Ketamine Therapy Risk

Clinically supervised ketamine therapy differs significantly from unsupervised use. The care model and safety protocols matter just as much as the medicine itself.

Responsible ketamine therapy relies on clinical safeguards that guide the entire patient journey. Mindbloom implements these principles through an evidence-backed, comprehensive care model.

Medical and Psychiatric Screening Before Treatment

Thorough intake evaluation serves as the first layer of risk reduction for any patient. Clinicians assess not just whether someone qualifies, but how to personalize the protocol based on individual clinical factors.

This includes tailoring the dosing, session frequency, and monitoring intensity to match your specific health profile. By identifying potential contraindications early, providers ensure that only medically appropriate candidates proceed to treatment.

Session Safety Planning at Home

The at-home safety framework ensures that your environment is secure before you begin. A peer treatment monitor is required to be present during every Mindbloom session to provide physical presence and peace of mind.

The environment is prepared in advance using guidance and materials, and sessions follow a defined protocol with preparation, the session itself, and a post-session transition period. Mindbloom's Bloombox provides all session essentials, and the Mindbloom App guides each step of the process.

Integration and Ongoing Clinical Support After Sessions

The therapeutic benefit of ketamine extends far beyond the session itself. Integration is the process of making meaning from the experience and translating insights into lasting change.

Mindbloom's model includes guide coaching sessions, unlimited Group Integration Circles, unlimited guide messaging, and clinician consults for ongoing dosage support. This evidence-backed model is informed by Mindbloom's two peer-reviewed, real-world outcomes studies — both published in the Journal of Affective Disorders and both conducted on actual Mindbloom clients — which provide ongoing data to refine safety protocols and treatment effectiveness.¹

Conclusion

Ketamine therapy is a clinically established treatment with a well-documented safety profile, but it is not appropriate for everyone. The conditions and considerations outlined in this article reflect the thoroughness of the screening process — designed to ensure that every person who begins treatment is set up for a safe and effective experience.

Eligibility is a clinical conversation, not a self-diagnosis. If you are unsure whether ketamine therapy is right for you, the first step is to schedule a clinician-led evaluation to discuss your unique health profile.

Disclaimer and Safety Information

IMPORTANT SAFETY INFORMATION ‍Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

‍OFF-LABEL USE DISCLOSURE ‍Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.